Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal

Journal of Clinical Virology

Volumn 61, Issue 4, 2014, Pages 600-603

  Viganò, Mauro ^a   Brocchieri, Alessandra ^b   Spinetti, Angiola ^c   Zaltron, Serena ^c   Mangia, Giampaolo ^a   Facchetti, Floriana ^a   Fugazza, Alessandro ^b   Castelli, Francesco ^c   Colombo, Massimo ^a   Lampertico, Pietro ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Adverse drug reaction; Entecavir; Fanconi syndrome; Hepatitis B virus; Tenofovir

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CALCIUM; CREATININE; ENTECAVIR; POTASSIUM; SODIUM; TENOFOVIR DISOPROXIL; ADENINE; ANTIVIRUS AGENT; GUANINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BICARBONATE BLOOD LEVEL; CASE REPORT; CREATININE BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FANCONI RENOTUBULAR SYNDROME; GLUCOSURIA; HEPATITIS B; HUMAN; ITALIAN (CITIZEN); KIDNEY TUBULE FUNCTION; MALE; MIDDLE AGED; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; ISOLATION AND PURIFICATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIRUS LOAD;

ADENINE; ANTIVIRAL AGENTS; FANCONI SYNDROME; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; TENOFOVIR; TREATMENT OUTCOME; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 84922729207     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.09.016     Document Type: Article

References (11)

1. Marcellin P., Gane E., Tsai N., Flisiak R., Petersen J., Gurel S., et al. Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Hepatology 2013, 58(4 (Suppl.)):649A.
2. Pol S., Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat 2012, 19:377-386.
3. Hall A.M., Hendry B.M., Nitsch D., Connolly J.O. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011, 57:773-780.
4. Izzedine H., Launay-Vacher V., Isnard-Bagnis C., Deray G. Drug-induced Fanconi's syndrome. Am J Kidney Dis 2003, 41:292-309.
5. Gracey D.M., Snelling P., McKenzie P., Strasser S.I. Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther 2013, 18:945-948.
6. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185.
7. Marcellin P., Heathcote E.J., Buti M., Gane E., de Man R.A., Krastev Z., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359:2442-2455.
8. Izzedine H., Hulot J.S., Villard E., Goyenvalle C., Dominguez S., Ghosn J., et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006, 194:1481-1491.
9. Rodri{dotless}guez-Novoa S., Labarga P., Soriano V., Egan D., Albalater M., Morello J., et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009, 48:e108-e116.
10. Nishijima T., Komatsu H., Higasa K., Takano M., Tsuchiya K., Hayashida T., et al. Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study. Clin Infect Dis 2012, 55:1558-1567.
11. Lampertico P., Soffredini R., Yurdaydin C., Idilman R., Papatheodoridis G.V., Margariti E., et al. Four years of tenofovir monotherapy for NUC nai{dotless}ve field practice European patients suppress HBV replication in most patients with a favorable renal safety profile but do not prevent HCC in patients with or without cirrhosis. Hepatology 2013, 58(Suppl. 1):653A.